Prof Constantine Tam
Clinical (Professor)
Department of Medicine
911 Scholarly works
7 Projects
HIGHLIGHTS
2022
Journal article
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
DOI: 10.1182/blood.20220160402022
Journal article
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
DOI: 10.1182/bloodadvances.20220083252022
Journal article
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
DOI: 10.1182/blood.20210127752022
Journal article
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
DOI: 10.1182/bloodadvances.20210056212022
Research grants (ARC, NHMRC, MRFF)
Understanding and Averting Blood Cancer Resistance to Therapy
2019
Research grants (ARC, NHMRC, MRFF)
The Aim2 Study: Genomically Guided Novel Combination Treatment of Mantle Cell Lymphoma
2017
Research Grant
Centre of Research Excellence in Chronic Lymphotic Leukemia at the Victorian Comprehensive Cancer Centre
RECENT SCHOLARLY WORKS
2026
Journal article
First-line treatment for CLL in the era of targeted therapy
DOI: 10.1038/s41408-025-01434-22026
Journal article
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
DOI: 10.1182/blood.20250323072026
Journal article
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
DOI: 10.1182/bloodadvances.20260201232026
Journal article
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
DOI: 10.1016/S2352-3026(26)00037-22026
Journal article
An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL
DOI: 10.1182/bloodadvances.20250185362026
Journal article
Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.
DOI: 10.1182/blood.20250327572026
Journal article
Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B-cell malignancies
DOI: 10.1016/j.esmoop.2026.1060862026
Journal article
Reply to: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial
DOI: 10.21037/actr-26-0007